简易评分识别射血分数保留心衰中转甲状腺素蛋白淀粉样心肌病风险
本研究基于梅奥诊所666例因疑似ATTR-CM接受PYP扫描的HFpEF患者,回顾性推导并验证了一个包含6个变量的简易评分(年龄、男性、高血压、相对室壁厚度>0.57、后壁厚度≥12 mm、射血分数<60%),评分范围-1至10。该评分在推导队列中AUC为0.89(95%CI 0.86-0.92),并在三个验证队列中保持良好区分度(AUC≥0.84)。评分≥6分在ATTR-CM患病率≥10%的场景下阳性预测值≥25%。
要点
- 6变量评分(年龄、男性、高血压、相对室壁厚度>0.57、后壁厚度≥12 mm、射血分数<60%)可预测HFpEF患者ATTR-CM风险。
- 评分≥6分在患病率≥10%时阳性预测值≥25%,可指导PYP扫描选择。
- 在HFpEF临床试验中,11%-35%的男性及0%-6%的女性评分≥6分。
核心结论
- 一个简单的6变量临床评分可用于指导PYP的使用,并提高社区中HFpEF患者ATTR-CM的识别。
- 需要在更大和更多样化的人群中进一步验证。
研究设计与样本
- 回顾性队列研究,纳入666例射血分数≥40%且疑似ATTR-CM并转诊至梅奥诊所接受PYP扫描的心衰患者(2013年5月10日至2020年8月31日)。
- 推导队列n=416(ATTR-CM患病率45%),转诊验证队列n=250(患病率48%),社区验证队列n=286(患病率6%),外部验证队列n=66(患病率39%)。
- 通过逻辑回归模型推导评分,并在三个验证队列及四项跨国HFpEF临床试验中评估。
主要发现
- 评分变量包括年龄、男性、高血压诊断、相对室壁厚度>0.57、后壁厚度≥12 mm、射血分数<60%(评分范围-1至10)。
- 推导队列区分度AUC 0.89(95%CI 0.86-0.92;P<.001),校准Hosmer-Lemeshow χ2=4.6(P=.46)。
- 转诊验证队列AUC≥0.84(P<.001),校准χ2=2.8(P=.84);社区验证队列校准χ2=4.4(P=.35);外部验证队列校准χ2=2.5(P=.78)。
- 评分≥6分在临床相关ATTR-CM患病率(≥10%)场景下阳性预测值≥25%。
- 在HFpEF临床试验中,11%至35%的男性患者和0%至6%的女性患者评分为高风险(≥6分)。
关键数值与推荐
- 评分≥6分定义为高风险,在ATTR-CM患病率≥10%时阳性预测值≥25%。
- 评分变量及赋值:年龄、男性、高血压诊断、相对室壁厚度>0.57、后壁厚度≥12 mm、射血分数<60%(具体分值未在摘要中报告)。
临床怎么用
- 对于HFpEF患者,可使用该6变量评分评估ATTR-CM风险,评分≥6分时考虑进行PYP扫描。
- 该评分有助于在社区环境中提高ATTR-CM的识别率。
局限性
- 需要在更大和更多样化的人群中进一步验证。
- 研究为回顾性设计,部分队列样本量较小(如外部验证队列n=66)。
- 研究人群以白人为主,黑人和其它种族代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart failure (HF) with preserved ejection fraction (HFpEF). Technetium Tc 99m pyrophosphate scintigraphy (PYP) enables ATTR-CM diagnosis. It is unclear which patients with HFpEF have sufficient risk of ATTR-CM to warrant PYP. OBJECTIVE: To derive and validate a simple ATTR-CM score to predict increased risk of ATTR-CM in patients with HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 666 patients with HF (ejection fraction ≥ 40%) and suspected ATTR-CM referred for PYP at Mayo Clinic, Rochester, Minnesota, from May 10, 2013, through August 31, 2020. These data were analyzed September 2020 through December 2020. A logistic regression model predictive of ATTR-CM was derived and converted to a point-based ATTR-CM risk score. The score was further validated in a community ATTR-CM epidemiology study of older patients with HFpEF with increased left ventricular wall thickness ([WT] ≥ 12 mm) and in an external (Northwestern University, Chicago, Illinois) HFpEF cohort referred for PYP. Race was self-reported by the participants. In all cohorts, both case patients and control patients were definitively ascertained by PYP scanning and specialist evaluation. MAIN OUTCOMES AND MEASURES: Performance of the derived ATTR-CM score in all cohorts (referral validation, community validation, and external validation) and prevalence of a high-risk ATTR-CM score in 4 multinational HFpEF clinical trials. RESULTS: Participant cohorts included were referral derivation (n = 416; 13 participants [3%] were Black and 380 participants [94%] were White; ATTR-CM prevalence = 45%), referral validation (n = 250; 12 participants [5%]were Black and 228 participants [93%] were White; ATTR-CM prevalence = 48% ), community validation (n = 286; 5 participants [2%] were Black and 275 participants [96%] were White; ATTR-CM prevalence = 6% ), and external validation (n = 66; 23 participants [37%] were Black and 36 participants [58%] were White; ATTR-CM prevalence = 39%). Score variables included age, male sex, hypertension diagnosis, relative WT more than 0.57, posterior WT of 12 mm or more, and ejection fraction less than 60% (score range -1 to 10). Discrimination (area under the receiver operating characteristic curve [AUC] 0.89; 95% CI, 0.86-0.92; P < .001) and calibration (Hosmer-Lemeshow; χ2 = 4.6; P = .46) were strong. Discrimination (AUC ≥ 0.84; P < .001 for all) and calibration (Hosmer-Lemeshow χ2 = 2.8; P = .84; Hosmer-Lemeshow χ2 = 4.4; P = .35; Hosmer-Lemeshow χ2 = 2.5; P = .78 in referral, community, and external validation cohorts, respectively) were maintained in all validation cohorts. Precision-recall curves and predictive value vs prevalence plots indicated clinically useful classification performance for a score of 6 or more (positive predictive value ≥25%) in clinically relevant ATTR-CM prevalence (≥10% of patients with HFpEF) scenarios. In the HFpEF clinical trials, 11% to 35% of male and 0% to 6% of female patients had a high-risk (≥6) ATTR-CM score. CONCLUSIONS AND RELEVANCE: A simple 6 variable clinical score may be used to guide use of PYP and increase recognition of ATTR-CM among patients with HFpEF in the community. Further validation in larger and more diverse populations is needed.
引用
- Davies, Redfield, Scott, et al. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2022. PMID: 36069809. doi:10.1001/jamacardio.2022.1781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。